--- title: "The Deputy Director of the National Medical Products Administration met with the Deputy Director of the FDA, stating that both sides will continue to carry out pragmatic cooperation" type: "News" locale: "en" url: "https://longbridge.com/en/news/273907613.md" description: "Yang Sheng, Deputy Director of the National Medical Products Administration of China, met with Yang Du, Deputy Director of the FDA of the United States. Both sides affirmed the effectiveness of China-U.S. pharmaceutical regulatory cooperation and expressed their intention to continue practical cooperation to promote more high-quality products benefiting the people of both countries. The Chinese side introduced the latest developments in drug regulation and the review of the Implementation Regulations of the Drug Administration Law, while the U.S. side reported on key work such as ensuring the pharmaceutical supply chain, regulating digital health products, and managing the quality of medical devices, and engaged in in-depth exchanges on drug import and export policies, pharmacovigilance, and the application of new methodologies" datetime: "2026-01-27T23:09:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273907613.md) - [en](https://longbridge.com/en/news/273907613.md) - [zh-HK](https://longbridge.com/zh-HK/news/273907613.md) --- # The Deputy Director of the National Medical Products Administration met with the Deputy Director of the FDA, stating that both sides will continue to carry out pragmatic cooperation Yang Sheng, Deputy Director of the National Medical Products Administration of China, met with a delegation led by Yang Du, Deputy Director of the U.S. Food and Drug Administration (FDA), yesterday (27th). Both sides fully affirmed the positive results achieved in China-U.S. drug regulatory cooperation and expressed their intention to continue practical cooperation to jointly promote more and better products benefiting the people of both countries. The Chinese side introduced the latest progress in drug regulation in mainland China and reported on the review and approval of the Implementation Regulations of the Drug Administration Law. The U.S. side reported on key work in areas such as ensuring the drug supply chain, constructing a regulatory framework for digital health products, and building regulations for medical device quality management systems. Both sides also engaged in in-depth exchanges on drug import and export policies, pharmacovigilance, and the application of new methodologies ### Related Stocks - [002899.CN](https://longbridge.com/en/quote/002899.CN.md) - [002826.CN](https://longbridge.com/en/quote/002826.CN.md) ## Related News & Research - [](https://longbridge.com/en/news/281575238.md) - [Drug pricing deal to generate savings of $64.3 billion over 10 years, White House says](https://longbridge.com/en/news/285233665.md) - [FDA's top drug regulator ousted amid agency upheaval](https://longbridge.com/en/news/286795159.md) - [Premium skincare brand Forest Cabin will study L’Oreal, but not copy it: CEO interview](https://longbridge.com/en/news/286831488.md) - [AIB joins Qivalis consortium to develop regulated euro stablecoin](https://longbridge.com/en/news/287054515.md)